Glooko, a leading provider of intelligent, connected care solutions and remote patient monitoring (RPM) for people with diabetes and related chronic conditions, presented positive data from two recent studies on remote patient monitoring at the 2022 IDF World Diabetes Congress.
The first study presented by Team Glooko at the Congress, Cost and Outcomes of a Diabetes Remote Patient Monitoring System: A Simulation Analysis, was the company’s inaugural study using a health economics and outcomes research (HEOR) simulation model. In a randomized controlled trial of RPM and digital therapeutics (DTx), the intervention resulted in significantly improved HbA1c in patients with type 2 diabetes (T2D). Incorporating these results into a microsimulation model of longer-term complications, mortality and costs demonstrated the potential for RPM and DTx to elicit health gains and cost savings among people with diabetes.
The second study presented by Team Glooko, The Impact of Remote Patient Monitoring on Glycated Hemoglobin for Type 2 Diabetes: A Randomized Controlled Trial, demonstrated that a comprehensive 24-week RPM diabetes management program was more effective in improving HbA1c compared to usual care for adults with T2D.
These studies further showcase the clinical and economic benefits of the Glooko platform, which is sold to healthcare providers globally, and available for free as a mobile app to patients.
Team Glooko will continue to highlight the benefits of our connected care platform for diabetes and related chronic conditions at industry events in 2023.
MKT-0413 01
